Effectiveness of RSV Vaccines against RSV-Associated Thromboembolic Events
We evaluated effectiveness of respiratory syncytial virus (RSV) vaccines against RSV-associated thromboembolic events among community-dwelling Medicare fee-for-service beneficiaries >65 years of age in the United States enrolled during October 1, 2023-March 30, 2024. RSV vaccines protected against RSV-associated thromboembolic events (effectiveness 79% [95% CI 74%-83%]) in the same season as vaccine receipt.
Authors
- Amber Kautz (ORCID: https://orcid.org/0000-0001-8463-9167)
- Yixin Jiao (ORCID: https://orcid.org/0000-0002-1767-4680)
- Heng-Ming Sung
- Yangping Chen
- Yoganand Chillarige (ORCID: https://orcid.org/0000-0002-8020-6839)
- Morgan Najdowski
- Andrea J Chavez
- Amanda B Payne
- Yenlin Lai
- Ruth Link-Gelles
- Yue Zhang
- Josephine Mak
- Ryan E. Wiegand
Publication Details
- Journal
- Emerging infectious diseases
- Published
- 2026-02-01
- DOI
- https://doi.org/10.3201/eid3202.251520
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00